Warning: The NCBI web site requires JavaScript to function. more...
Generate a file for use with external citation management software.
Autologous hematopoietic cell transplantation following high-dose immunosuppressive therapy for advanced multiple sclerosis: long-term results.
Bowen JD, Kraft GH, Wundes A, Guan Q, Maravilla KR, Gooley TA, McSweeney PA, Pavletic SZ, Openshaw H, Storb R, Wener M, McLaughlin BA, Henstorf GR, Nash RA.
Bone Marrow Transplant. 2011 Nov 7. doi: 10.1038/bmt.2011.208. [Epub ahead of print]
Related citations
CD49d blockade by natalizumab therapy in patients with multiple sclerosis increases immature B-lymphocytes.
Lesesve JF, Debouverie M, Decarvalho Bittencourt M, Béné MC.
Bone Marrow Transplant. 2011 Nov;46(11):1489-91. doi: 10.1038/bmt.2010.328. Epub 2011 Jan 17. No abstract available.
Hematopoietic SCT for the treatment of multiple sclerosis.
Atkins H.
Bone Marrow Transplant. 2010 Dec;45(12):1671-81. Epub 2010 Aug 9. Review.
T-cell clones persisting in the circulation after autologous hematopoietic SCT are undetectable in the peripheral CD34+ selected graft.
Dubinsky AN, Burt RK, Martin R, Muraro PA.
Bone Marrow Transplant. 2010 Feb;45(2):325-31. Epub 2009 Jun 22.
CD49d blockade by natalizumab in patients with multiple sclerosis affects steady-state hematopoiesis and mobilizes progenitors with a distinct phenotype and function.
Jing D, Oelschlaegel U, Ordemann R, Hölig K, Ehninger G, Reichmann H, Ziemssen T, Bornhäuser M.
Bone Marrow Transplant. 2010 Oct;45(10):1489-96. Epub 2010 Jan 25.
Filters: Manage Filters
Your browsing activity is empty.
Activity recording is turned off.
Turn recording back on